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Melbourne, Parkville, Victoria, AustraliaAbstractIn many countries now, vaccination of young adolescent girls with prophylactic human papillomavirus (HPV) vaccines has been rolled out as a
public health programme. In countries where coverage has been high, this has led to dramatic reductions in cervical high-grade precancerous
lesions, as well as genital warts. A reduction in circulating vaccine-related HPV types has also been demonstrated. With the introduction of
gender-neutral approaches incorporating universal vaccination of pre-adolescent boys in some countries, implementation of post-vaccine
monitoring will be critical to evaluate the incremental impact of male vaccination. In contrast to cervical screening programmes,
population-wide screening for HPV infection or related disease in males is not recommended; hence real-time monitoring of HPV vaccine
effectiveness in males will require dedicated surveillance strategies. Monitoring the prevalence of circulating genital HPV types using a
sentinel surveillance model could offer a good surrogate marker of early vaccine effectiveness in males. However, such an approach
requires careful consideration of the most appropriate anatomical sites from which to collect specimens, the best sampling methods and
the most sensitive assays to use. Additionally, in assessing an accurate measure of the impact of HPV vaccination in the male population,
the effect of herd protection will need to be assessed, as most male programmes will commence in the setting of established female
programmes. This poses an interesting epidemiological challenge.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: suzanne.garland@thewomens.org.auIntroductionThe implementation of prophylactic vaccines against human
papillomavirus (HPV) is arguably one of the most signiﬁcant
developments in cancer prevention of our time. HPV is largely a
sexually transmitted infection, with disease manifestations in
both genders. In addition to the well-known relationship be-
tween HPV and cervical disease, anogenital HPVs are theMicrobiol Infect 2015; 21: 834–841
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.038causative agent of genital warts, a proportion of anal, penile,
vaginal and vulvar cancers, as well as some oropharyngeal
cancers [1]. With proven efﬁcacy in preventing male disease
[2,3], licensure of HPV vaccines for males has followed that for
females, with many countries now funding or recommending
universal vaccination of pre-adolescent boys.
Male vaccination has not been without controversy howev-
er, with some arguing that the incremental beneﬁt of adding
males to female vaccination campaigns does not justify the cost
[4]. To inform debate on the beneﬁt of the male programme, it
is critical that the effects of male vaccination are properly
measured. In this review we discuss the efﬁcacy and safety of
HPV vaccines in males and summarize the current status of
implementation, as a prelude to considering how best to
measure the effectiveness of male HPV vaccination.ious Diseases. Published by Elsevier Ltd. All rights reserved
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vaccines have been shown in phase III clinical vaccine trials to be
safe, efﬁcacious and immunogenic in young women 18–26
years of age [5–8], with safety, efﬁcacy and immunogenicity also
demonstrated in mature women, up to 45 years of age [9,10].
Moreover the effectiveness of female vaccination in real world
settings is not only evident in the translation to signiﬁcant re-
ductions in vaccine-related HPV infections, but also disease
manifestations such as genital warts and cervical intraepithelial
neoplasia [11–14]. In addition, where 4vHPV coverage of the
target female population has been high, a parallel reduction in
genital warts has been observed in heterosexual males: a
consequence of herd protection [15]. Surprisingly, decreases in
the rates of genital wart diagnoses among vaccine-eligible fe-
males and same-aged males has been observed in England
following 2vHPV vaccination [16]. Moderate 2vHPV vaccine
efﬁcacy against low-risk HPV types, through cross protection
or cell-mediated immunity, may help to explain this observation
[17].
Although these vaccines were developed to reduce the
burden of disease from cervical cancers, the vast majority of
which are caused by infection with high-risk HPVs (HPV types
16 and 18 contribute to 70% worldwide), a proportion of other
anogenital cancers are also caused by the same HPV types.
These include approximately 70% of cancers of the vagina, 43%
of vulvar, 50% of penis, 88% of the anus and 13–56% of the base
of tongue and oropharynx [1]. As a result, current vaccines
have the potential to signiﬁcantly reduce the burden of HPV-
associated diseases in both men and women.
The 4vHPV vaccine has been evaluated in young men aged
16–26 years, in similarly designed phase III clinical trials to
those used in females and has been shown to be similarly
immunogenic, efﬁcacious and safe, not only in preventing
vaccine-related HPV infections, but also genital warts and anal
intraepithelial neoplasia [2,3]. In a subgroup analysis of men
who have sex with men (MSM), an 89% reduction in genital
warts (95% CI 8.8–95.4) and ~75% reduction in high-grade anal
lesions (anal intraepithelial neoplasia stage 2/3) (95% CI
65.3–97.9) was reported [2]. Consequently the 4vHPV vaccine
was licenced in October 2009 by the US Food and Drug
Administration for use in males aged 9–26 years in the USA,
with several other countries following thereafter.
A next-generation vaccine, the nonavalent (9vHPV) has
recently been reported in phase III trials to be safe, efﬁcacious,
immunogenic and non-inferior to the 4vHPV vaccine in young
women aged 16–26 years [18]. Preliminary unpublished but
presented results of other studies indicate that safety andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyimmunogenicity also extend to men aged 16–26 years and girls
and boys aged 9–15 years (EUROGIN 2015 Congress, ab-
stracts 0C 6-6 Castellsague et al. and 0C 6-3 Olsson et al.,
respectively). Based on these ﬁndings, licensure occurred in the
USA by the US Food and Drug Administration in December
2014 [19] and by Health Canada in February 2015 [20], with
the US Advisory Committee on Immunization Practices voting
in February 2015 to include the 9vHPV vaccine in recom-
mended routine vaccination for 11- to 12-year-old girls and
boys [21]. We await the pricing relative to the 4vHPV vaccine.Current male vaccination implementation in
public health programmesTo date, very few countries have implemented male 4vHPV
vaccination as part of national public health programmes.
Implementation of male 4vHPV vaccination into public health
programmes followed that of the female programme in the USA,
with endorsement by the US Advisory Committee on Immu-
nization Practices in October 2011 for routine vaccination of
males aged 11–12 years, in a clinic-based delivery system [22]
with some state and federal funding available. Coverage for
boys stands at approximately half the rate for girls according to
the most recent data (13.9% for males aged 13–17 years in
2013, 37.6% for females [23]). In Australia, implementation of
male vaccination occurred in December 2012, with the
Australian Technical Advisory Group on Immunisation (ATAGI)
endorsing an ongoing school-based government-funded pro-
gramme commencing in February 2013. This programme targets
12- to 13-year-old boys and included a 2-year catch-up for 14-
to 15-year-olds to the end of 2014. Although population-based
estimates are not yet available, preliminary data suggest coverage
of the school-based male vaccination programme is only slightly
lower than that achieved to date in the female programme [24].
In 2012, Austria announced that it planned to introduce a na-
tional publicly funded HPV vaccination programme covering
both males and females from the outset [25]. Other countries
are beginning to follow suit with two of 13 provinces in Canada
currently offering publicly funded campaigns [25] and ongoing
debate in the UK about whether to extend publicly funded
vaccination to males [26].How best to measure HPV vaccine
effectiveness in males?Vaccine safety and effectiveness are key to any successful im-
munization programme. Although pre-clinical end-point efﬁcacyand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 834–841
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of vaccines, the role of post-licensure surveillance has become
increasingly recognized as a necessary complement to ensure
that vaccine efﬁcacy is translated into a reduction in disease in
real world settings [27].
Comprehensive post-licensure monitoring of HPV vaccina-
tion programmes involves collecting data for a variety of in-
dicators pertaining to vaccine coverage, safety and disease
outcomes—the primary disease outcome being the reduction
in cervical and other HPV-associated cancers. Considering the
long lead time between initial HPV exposure and the develop-
ment of cancer, monitoring earlier outcomes such as HPV
infection, incident genital warts and prevalence of screen-
detected cervical abnormalities (cervical intraepithelial
neoplasia) provides important, early surrogate measures of
vaccine effectiveness on a population level.
With the existence of well-established population-based
cervical cancer screening programmes and linked cytology,
cancer and HPV vaccine registries, high-income countries such
as Australia are well placed to directly monitor early end points,
namely reduction in screen-detected histologically proven
cervical abnormalities, following implementation of the HPV
vaccination programme in females [28]. However, although
post-licensure monitoring of the HPV vaccine in males requires
some of the same systems as for females, direct monitoring of
early end points is challenging given the absence of any equiv-
alent of Papanicolaou smear screening initiatives.
Monitoring temporal trends in genital warts incidence can
provide a good, albeit indirect, early measure of the population
impact of HPV vaccination [29]. The short incubation period
and symptomatic nature of genital warts make this a good
candidate for ongoing surveillance. However, as genital warts
are not notiﬁable in most countries, accurate estimates of
incidence and prevalence are not widely available and to date
come mostly from clinic, rather than population-based samples
[15]. Additionally, data from modelling studies suggest that the
population level impact of HPV vaccination is likely to differ by
HPV type; hence monitoring trends in HPV types 6 or 11
related disease (i.e. genital warts) alone is likely to be a poor
proxy for changes in the burden of HPV 16 or 18 and related
disease [30].
In general, genital prevalence of both vaccine and non-
vaccine HPV types in men appears to be high, with estimates
of any-type prevalence typically above 20% [31–35]. In the HPV
Infection in Men (HIM) study, a large ongoing prospective study
of heterosexual men recruited from the general population,
universities and healthcare settings in Brazil, Mexico and USA,
the baseline prevalence of genital any-type HPV was 53.1%
among 3326 healthy heterosexual males aged 18–70 years [36].
In the same study, anal canal any-type HPV prevalence wasClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect12.2% among 1305 men who have sex with women and 47.2%
among 176 MSM, with MSM much more likely to test positive
for multiple types [37]. In addition, genital HPV prevalence
appears to be high even in young, relatively sexually inexperi-
enced men. In the baseline visit of the phase III clinical trial
evaluating 4vHPV among 3463 young heterosexual men aged
16–26 years, one in ﬁve (21.2%) had detectable HPV at any
genital site [38]. In the same trial, nearly half (48.1%) of 602
young MSM tested positive for any HPV type, at any genital or
anal site, at the baseline visit [39].
HPV genoprevalence estimates do vary greatly across studies
[32,35]. In a recent global systematic review by Smith et al.
including 64 studies covering 14 800 men in 23 countries, the
prevalence of genital HPV ranged from 1% to 84% among low-
risk men and from 2% to 93% among high-risk men [35]. An
earlier systematic review by Dunne et al. found a similar het-
erogeneity [32]. This variation may be attributable to differ-
ences in source populations, as well as differences in the
anatomical sites sampled, and sampling and laboratory detection
methodologies used between studies. Nevertheless, monitoring
changes in the prevalence of genital HPV genotypes among
young sexually active men could offer a valid early-term indi-
cator of vaccine impact in this population.
The relatively high rate of clearance of HPV DNA detected
in males [40] suggests that the detection of genital HPV DNA is
less a marker of a host-signiﬁcant ‘infection’. than it is an indi-
cator of viral deposition. For the purposes of evaluating vaccine
effectiveness in the population as a whole, however, this is
sufﬁcient because it allows tracking of the overall circulating
pool of virus and changes in type prevalence.HPV genotype surveillanceThe objectives of a long-term HPV genotype surveillance sys-
tem will be to assess how effective the vaccine has been directly
and through herd protection, and ultimately to monitor for
evidence of HPV genotype cross-protection and/or replace-
ment. In addition, the system would need to monitor any peaks
in infection in older vaccinated populations, which may indicate
waning immunogenicity. To accomplish these objectives, an
ongoing surveillance system would need to collect a sufﬁcient
number of samples to detect signiﬁcant changes in HPV prev-
alence over time in the populations of interest.
The implementation of an HPV genotype surveillance system
for males is methodologically challenging. HPV DNA testing is
not currently used for screening and there is no routine pro-
cess for HPV genotyping. In addition, sampling populations of
interest in a manner that is repeatable and representative is
difﬁcult. Population-level random sampling is not feasible forious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 834–841
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under-represented. Similarly, passive surveillance such as is
done to monitor notiﬁable infectious diseases is not feasible,
because of the asymptomatic and transient nature of most HPV
infections, as well as the long incubation period for disease
manifestation. Furthermore, to assess the impact of HPV
vaccination in males, accurate data on HPV prevalence before
vaccine implementation are needed. However, reliable
population-based data on HPV prevalence are unavailable and
past genoprevalence surveys are of little use in informing esti-
mates of baseline prevalence, due to the heterogeneity among
studies.
Adopting a sentinel surveillance model could offer the most
appropriate strategy to monitor the effectiveness of male HPV
vaccination programmes. This approach has previously been
demonstrated to be an appropriate and effective strategy to
monitor post-vaccination HPV genotype prevalence [41]. In
general terms, a sentinel surveillance strategy would involve
prospective collection of specimens for HPV genotyping at
geographically diverse sites and services such as sexual health
or general practice clinics, with each site providing a certain
number of specimens per year, on an ongoing basis. If repeat-
able recruitment, sampling and detection methodologies are
established at sentinel sites and remain constant over time,
monitoring HPV genotypes using this strategy will allow for the
detection of changes in circulating HPV types [42].
In the design of a sentinel surveillance programme, consid-
eration must be given to the most appropriate anatomical sites
or specimens to sample, the best sampling methods and the
most sensitive assays to use. With respect to anatomical site,
sampling of the penile shaft, the glans, the coronal sulcus and
the scrotum provides the highest detection rates as these are
most likely to become colonized with HPV during intercourse
[43]. Sampling at other sites such as the urethra, semen or urine
are signiﬁcantly less sensitive than penile and scrotal sampling
and contribute little to estimates of HPV prevalence [43–45]. In
higher-risk MSM populations, sampling of the anal canal should
be considered as in this population HPV is more frequently
detected here than on the penis or scrotum [46,47].
Male sampling method
Sampling the penile surface to obtain an adequate sample is
challenging because it requires the removal and collection of
keratinized epithelial cells. Accordingly, it is recommended that
the entire surface of shaft, glans, and optionally scrotum, be
swabbed ﬁrmly for 2–3 minutes, including over and under the
foreskin if it is present [48]. Although gentle abrasion with an
emery board, followed by collection with a moistened ﬂocked
swab is deemed the most successful method, in a recent
comparative study, there was little difference in sampleClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyadequacy and HPV detection rates between swabbing with and
without abrasion. Swabbing without abrasion is more accept-
able and less uncomfortable for participants and may improve
recruitment rates, particularly where participants self-collect
samples [49]. Self-sampling of penile samples is widely
accepted by MSM and heterosexual men, and produces samples
of similar quality to clinician-collected samples [50].
Anal sampling is performed with either a dry or moistened
Dacron or ﬂocked swab, inserted approximately 2 cm into the
anal canal and ﬁrmly rotated as it is removed [43]. Self-sampling
of the anal canal by MSM has been successful in a number of
studies, with nearly identical detection rates to clinician-
collected sampling [51,52].
Measurements for adequacy of sampling and absence of in-
hibitors are also important parameters for HPV testing. This is
particularly so for self-collected samples, where adequacy of
sampling is reliant on the participants following the protocols
given to them. In addition, measurement of the effect of in-
hibitors in the samples, from the anal canal in particular, are
critical to ensure that ampliﬁcation reactions are not adversely
affected by the presence of inhibitory substances which are not
adequately removed during the nucleic acid extraction pro-
cesses. Detection of an internal control such as the human
β-globin gene as a marker of sample adequacy, as well as a
measure of inhibitors, should be routinely performed to ensure
that a negative result is not due to poorly collected sample or
inhibitory substances [53].
HPV assays
There are no commercially available HPV assays approved for
diagnostic use by the US Food and Drug Administration or the
Australian Therapeutic Goods Administration (TGA) for male
samples, but several have been marked European Conformity
mark-In Vitro Diagnostics (CE-IVD) compliant for diagnostic
use in Europe, including for men. The majority of assays detect
some of the mucosal genotypes, with some simultaneously
providing genotyping information [54,55]. Most assays report
only the detected presence of high-risk HPV genotypes,
whereas others include partial genotyping for HPV 16, 18 and/
or 45. Full genotyping assays, such as the commonly-used
Roche Linear Array, identify a range of individual genotypes
and are the most appropriate for surveillance. These very
sensitive assays are capable of identifying up to 37 individual
genotypes including all vaccine-targeted types, the remaining
high-risk genotypes and additional low-risk genotypes. A
drawback of full-genotyping assays that use consensus primer
sets such as PGMY and GP5+/6+ is the tendency for HPV 16
and several other types to outcompete the ampliﬁcation of a
subset of genotypes that are less efﬁciently ampliﬁed by PCR,
which theoretically has the potential to artiﬁcially alterand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 834–841
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post-vaccinated populations [56–58]. This can be overcome by
using assays that rely on type-speciﬁc primer sets [58];
currently these assays generally identify a smaller range of ge-
notypes and are often more labour-intensive, but recently
developed assays may overcome these drawbacks.The complicating factor of herd protectionIn countries such as Australia, where vaccine coverage has been
high, the earlier commencement of female vaccination pro-
grammes has already had an impact on rates of infection and
disease in males [15,41]. The mechanism for this effect is hy-
pothesized to be a reduction in the total pool of circulating
virus, as vaccinated females no longer provide a reservoir for
vaccine-preventable genotypes. This herd protection effect has
two implications for measuring vaccine effectiveness in settings
where male vaccination is introduced after female vaccination.
First, the beneﬁcial effect of female vaccination on the inci-
dence of male infection and consequent disease is unlikely to be
exhausted at the time when routine male vaccination is intro-
duced. In the absence of male vaccination, one would expect a
continuing decline in male HPV genoprevalence due to female
vaccination. The impact of female vaccination will therefore be
a confounding factor in measuring the impact of male vaccina-
tion on male disease. To accurately measure the impact of male
vaccination on male infection, it is the incremental additional
decline, beyond the decline due to female vaccination, that is of
interest. However, the decline in infection attributable to fe-
male vaccination will be difﬁcult, if not impossible, to isolate.
The dramatic decline in genital warts in settings such as
Australia where female 4vHPV coverage has been high suggests
that this herd protection effect is likely to be signiﬁcant,
although higher-risk MSM populations do not appear to be
beneﬁting as yet [15,29]. The magnitude of this herd protection
effect has appropriately led to debate about the merits of public
funding for male vaccination programmes [4,25,59].
Second (the corollary of the ﬁrst), male vaccination will
contribute to a reduction in the pool of circulating HPV and
thereby confer a beneﬁt to females, in the form of an incre-
mental decline in female infection and disease. A full measure of
the effectiveness of male vaccination would need to take ac-
count of this beneﬁt accruing to females.
It is important to note however that the incremental beneﬁts
of including males in routine vaccination programmes will differ
between countries that introduce male vaccination against a
background of high female vaccine coverage (such as Australia),
those that introduce male vaccination against a background of
moderate female coverage (such as the USA), or countries thatClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectintroduce both female and male vaccination simultaneously.
Modelling the impact of male vaccination with vaccine efﬁcacy
of 99% and female coverage of 70% (which accords with Aus-
tralia’s current female coverage rate), Brisson et al. estimated
that vaccinating boys would result in an extra incremental
reduction of around 20% in HPV 16/18 incidence over 70 years,
compared with vaccinating girls alone [60]. The incremental
beneﬁt is likely to be even higher where female coverage is
lower. This, combined with the need to protect MSM who will
beneﬁt less from herd protection and the equity beneﬁts of a
gender-neutral approach, suggest that male vaccination is
warranted.The role of seroprevalence surveillanceGiven the absence of routine HPV infection surveillance and
notiﬁcation regimens, and the invasive nature of genopreva-
lence surveys, it has been argued that seroprevalence might be
a better way to monitor the impact of vaccination pro-
grammes [61]. Serosurveillance can contribute to the ongoing
evaluation of vaccine efﬁcacy by measuring immunological
response to vaccination and monitoring for waning antibody
titres. In jurisdictions without vaccination registries, seros-
urveillance can also provide an indication of vaccine coverage,
as vaccination can be distinguished from natural infection on
the basis that it results in higher antibody titres [62]. Seros-
urveillance can provide information about changes in the
epidemiological dynamics of HPV infection related to vacci-
nation [62], but given that exposure to HPV DNA does not
always result in a serological response [61,63,64], seropreva-
lence cannot substitute for genoprevalence as a measure of
circulating virus.ConclusionsThe introduction of highly efﬁcacious prophylactic vaccines
against HPV combined with population-based vaccination
campaigns is likely to bring about signiﬁcant changes in the
incidence of HPV infection and HPV-related disease in men and
women. As with any public health measure, there is a need to
quantify the impact of HPV vaccination in order to monitor
cost-effectiveness, modify programmes where indicated based
on the ﬁndings, and inform future vaccine development. This is
underway with female vaccination, where pre-existing cervical
cancer screening programmes in many jurisdictions provide a
convenient source of data on early changes to disease end
points, as well as specimens for HPV prevalence studies. In the
absence of an equivalent screening programme for males,ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 834–841
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lenging. Key components of a system to measure HPV vaccine
effectiveness in males include vaccination programme evalua-
tion, sentinel surveillance comparing baseline genoprevalence
with post-vaccine genoprevalence, and disease end-point
monitoring through disease registries. A review of the avail-
able literature suggests that a well-designed sentinel surveillance
programme would include self-collected moistened ﬂocked
swab of penile shaft, glans, coronal sulcus and scrotum, tested
using a validated, licensed, full genotyping assay. Australia is
trialling a sentinel surveillance programme with these features;
we await the results.Transparency declarationThe authors declare that they have no conﬂicts of interest.References[1] Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J,
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